Select your Market
Financial results for Q1 2026
| Q1 2026 | Change (in %, compared to Q1 2025) | Organic change (in %, compared to Q1 2025) |
|---|---|---|---|
Group net sales | 5.1 | –2.8 | 2.9 |
EBITDA pre | 1.5 | –0.3 | 5.3 |
Life Science sales | 2.3 | 2.2 | 8.3 |
Healthcare sales | 2.1 | –3.0 | -3.4 |
Electronics sales | 0.8 | –13.9 | 4.2 |
Our first-quarter performance underlines the strength of the company’s diversified portfolio and its clear focus on complementary science and technology businesses. We upgrade our full-year 2026 financial guidance. At the same time, we sharpen the strategic direction of the company for the long-term.
Detailed information about the development of our business in the first quarter of 2026.
Downloads for the Media
Our Q2 2026 results will be published on August 6, 2026, at 7 a.m. (CEST). Our conference call for the media will take place at 09:30 a.m. (CEST), and the conference call for analysts at 2 p.m. (CEST)
Our Q3 2026 results will be published on November 12, 2026, at 7 a.m. (CEST). Our conference call for the media will take place at 09:30 a.m. (CEST), and the conference call for analysts at 2 p.m. (CEST)
Media Relations
Head of Investor Relations
+49 6151 72 91-5271
